Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jounce Therapeutics, Inc. - Common Stock (NQ:JNCE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jounce Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
4 Analysts Have This to Say About Jounce Therapeutics
Jounce Therapeutics (NASDAQ:JNCE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading... 
Via Benzinga
Jounce Therapeutics: Q1 Earnings Insights
Jounce Therapeutics (NASDAQ:JNCE) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company. 
Via Benzinga
Jounce Therapeutics Q1 2022 Earnings Conference Call On May 5, 2022 At 08:00 AM ET
Jounce Therapeutics (NASDAQ:JNCE) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
Recap: Jounce Therapeutics Q4 Earnings
Jounce Therapeutics (NASDAQ:JNCE) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Outlook For Jounce Therapeutics
Jounce Therapeutics (NASDAQ:JNCE) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement.... 
Via Benzinga
Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript
JNCE earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Viridian Therapeutics (NASDAQ:VRDN) shares rose 18.05% to $12.62 during Tuesday's pre-market session. The company's market cap stands at $120.9 million.... 
Via Benzinga
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares... 
Via Benzinga
Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript
JNCE earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Why Jounce Therapeutics Bounced Higher Today
The company gets a regulatory nod that will put $25 million in its pocket. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021
Upgrades Northcoast Research upgraded the previous rating for Casey's General Stores Inc ... 
Via Benzinga
Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25... 
Via Benzinga
Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript
JNCE earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
3 Buy-Rated Biotech Stocks Under $10
The biotech industry has been at the center of investor attention over the past year thanks to the COVID-19 pandemic and an accompanying global race for a vaccine. 
Via Talk Markets
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.